Thrombolytic therapy experience in an secondary care emergency department

Yıl 2019, Cilt: 12 Sayı: 2, 309 - 314, 28.05.2019

Mehmet Ali Aslaner Necmi Baykan

https://doi.org/10.31362/patd.515838

Cited By: 1

Öz

Purpose:
Although thrombolytic therapy is frequently used and the usage rates are well
defined in university and education-research hospitals in our country,
secondary care emergency departments (ED) utilization rates in national
literature are not known. With this study, it was aimed to create a new data
set which is insufficient in our country.

Materials
and Methods: The study was carried out retrospectively
between 2006 and 2008 in the secondary care ED of the biggest hospital of
........... province. Data set were included diagnoses, active substance,
complication status and 3-months mortality in addition to demographic
characteristics.

Results:
During the study period, 57 patients received thrombolytic therapy. The median
age of the patients was 68 (IQR 54-79) and the male gender ratio was 70.2%. The
frequency of thrombolytic therapy was 1.8 / 10.000 in all ED visits. Of all
diagnoses; the incidence of ischemic stroke was 50.9%, acute myocardial
infarction was 29.8%, arrest etiology was 10.5% and pulmonary thromboembolism
was 8.8%. Alteplase was used in 75.4% of the cases and tenecteplase was used in
24.6%. The mortality rate was 57.9% in all patients.

Conclusion:
Thrombolytic therapy was more frequently performed in patients with ischemic
stroke. Alteplase was the most commonly used thrombolytic agent because of its
wide spectrum of indications. It was thought that thrombolytic usage is very
low in in the secondary care emergency departments.

Anahtar Kelimeler

emergency department, thrombolytic therapy, alteplase, tenekteplase

İkinci basamak bir acil serviste trombolitik tedavi deneyimi

Öz

Amaç:
Trombolitik tedavi, ülkemizde üniversite ve eğitim-araştırma hastanelerinde
sıklıkla uygulanmakta ve kullanım oranları daha net olarak tanımlanmış olmasına
rağmen, ulusal literatürde ikinci basamak acil servis kullanım oranları
bilinmemektedir. Bu çalışma ile ülkemizde eksik olan, ikinci basamağa ait yeni
bir veri seti oluşturmak amaçlanmıştır.

Yöntem:
Çalışma 2006-2008 yılları arasında geriye dönük olarak, ........... ilinin en
büyük hastanesinin ikinci basamak acil servisinde gerçekleştirildi. Veri seti;
demografik özelliklerin yanı sıra, tanılar, kullanılan etken madde,
komplikasyon durumu ve 3 aylık mortalite olarak belirlendi.

Bulgular:
Çalışma periyodu boyunca 57 hastaya trombolitik tedavi verildi. Hastaların
ortanca yaşı 68 (IQR 54-79) ve erkek cinsiyet oranı %70,2 idi. Tüm çalışma
boyunca trombolitik tedavi kullanım sıklığı 1,8/10.000 acil servis başvurusu
olarak saptandı. Trombolitik tedavi uygulanan tanılar içerisinde; iskemik inme
%50,9 oranında, akut miyokard enfarktüsü %29,8, arrest etiyolojisi %10,5 ve pulmoner
tromboemboli %8,8 oranındaydı. Kullanılan ajanlardan alteplaz %75,4 oranında ve
tenekteplaz %24,6 oranında uygulandı. Tedavi uygulanan tüm hastaların 3 aylık
mortalite oranı %57,9’ idi.

Sonuç: Çalışmada, trombolitik tedavi uygulamasının
daha sıklıkla iskemik inme hastalarında uygulandığı görüldü. Alteplaz, geniş
endikasyon spektrumu nedeniyle en sık kullanılan trombolitik ajandı. Çalışma
sonucunda trombolitik kullanımının, özellikle ikinci basamak acil servislerde
oldukça düşük oranda olduğu düşünüldü.

Anahtar Kelimeler

acil servis, trombolitik tedavi, alteplaz, tenekteplaz

Kaynakça

• 1. Rivera-Bou WL, Chersich A. The Role of Fibrinolytic Therapy in the Emergency Department. Boletin de la Asociacion Medica de Puerto Rico 2016;108:61-4.
• 2. Hasanoğlu C. Trombolitik Tedavi: Kime, Ne zaman, Nasıl. Güncel Göğüs Hastalıkları Serisi 2015;3:34-44.
• 3. Kunt R. Treatment with Intravenous Thrombolysis in Acute Ischemic Stroke Through the Perspective of a State Hospital. Türk Beyin Damar Hast Derg 2016;22:91-9.
• 4. Duggal R, Harger N. The safe and appropriate use of thrombolytics in the emergency department. US Pharm 2011;36:11-6.
• 5. Johnson M, Bakas T. A review of barriers to thrombolytic therapy: implications for nursing care in the emergency department. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 2010;42:88-94.
• 6. Topçuoğlu MA, Arsava EM, Özdemir AÖ, Gürkaş E, Necioğlu Örken D, Öztürk Ş. Intravenous Thrombolytic Therapy in Acute Stroke: Problems and Solutions. Turk J Neurol 2017;23:162-75.
• 7. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2018;39:119-77.
• 8. Karaarslan S, Alihanoglu YI, Yildiz BS, et al. Appropriateness of the current guidelines on reperfusion treatment for patients applying to our hospital with ST-segment elevation acute myocardial infarction. Turk Kardiyol Dern Ars 2012;40:493-8.
• 9. Beton O, Zorlu A. Yoğun Bakımda Fibrinolitik Tedavi. Turkiye Klinikleri Journal of Cardiology Special Topics 2016;9:42-50.
• 10. Erkan L, Fındık S, Öztürk A, et al. Masif pulmoner tromboembolide trombolitik tedavi. Solunum Hastalıkları 2002;13:163-71.
• 11. Thrombolytic Therapy. 2017. (Accessed 08.12.2018, at https://emedicine.medscape.com/article/811234-overview.)
• 12. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet (London, England) 2001;357:1583-5.
• 13. Böttiger BW, Arntz H-R, Chamberlain DA, et al. Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest. New England Journal of Medicine 2008;359:2651-62.
• 14. Spohr F, Arntz HR, Bluhmki E, et al. International multicentre trial protocol to assess the efficacy and safety of tenecteplase during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest: the Thrombolysis in Cardiac Arrest (TROICA) Study. European journal of clinical investigation 2005;35:315-23.
• 15. Abraham P, Arroyo DA, Giraud R, Bounameaux H, Bendjelid K. Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper. Open Heart 2018;5:e000735.
• 16. Davydov L, Cheng JW. Tenecteplase: a review. Clinical therapeutics 2001;23:982-97; discussion 1.
• 17. Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular health and risk management 2009;5:249-56.
• 18. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. Journal of thrombosis and haemostasis : JTH 2014;12:459-68.
• 19. Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in the emergency department. Journal of thrombosis and thrombolysis 2007;23:101-5.